medRxiv preprint doi: https://doi.org/10.1101/2021.03.01.21252696; this version posted March 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Genetic variation of IFNL4 is associated with COVID-19.

Jose Maria R Saponi-Cortes[1*], Maria Dolores Rivas[2*], Juan F Sanchez Muñoz-Torrero[1], Alberto Costo[1], Carlos Martin[1], and Jose Zamorano[2].

Servicio de Medicina Interna[1] and Unidad de Investigacion[2], Complejo Hospitalario Universitario de Caceres, Caceres, Spain.

[*]These authors contributed equally to the work.

Corresponding author: jose.zamorano@salud-juntaex.es

Abstract

COVID-19 is caused by SARS-CoV-2, representing a major public health problem. To date no effective treatments have been established. Interferons (IFNs) are being intensively investigated due to their antiviral properties. Among them, Interferon lambda 4 (IFNL4) is known to have antiviral activity against viral infections of the upper respiratory tract, hepatitis C virus (HCV), but also coronaviruses. Importantly, genetic variants of IFNL4 have been associated with spontaneous viral clearance and response to IFNs-based therapies in HCV and other RNA virus infections. However, the presence of IFNL4 variants in COVID-19 is unknown. In this study, we investigated whether the rs12979860 polymorphism within IFNL4 was also associated with COVID-19. Our findings show that the presence of the CC allele of rs12979860 was significantly lower in COVID-19 patients compared to controls without COVID-19 (38% vs 55%, $p<0.001$). These results were not affected by sex, age, and severity of disease. These findings suggest that the CC allele of rs12979860 may also confer protection against COVID-19. This data may contribute to understanding the mechanisms of disease, the response to IFN-based treatments, and the racial differences observed in COVID-19.

Key Words: COVID-19, SARS-CoV-2, IFNL4, rs12979860

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.01.21252696; this version posted March 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Introduction

COVID-19 is a disease caused by the SARS-CoV-2 coronavirus (1). Most infected patients have a favorable prognosis, although severe pulmonary and systemic inflammation may develop in a small proportion of patients that can lead to multi-organ failure and death. The causes that determine susceptibility to infection have not yet been determined, although the severity seems to be associated with sex, age, and certain comorbidities. To date, effective treatments for COVID-19 have not yet been established and the efficacy of approved treatments remains limited (2).

Several studies have been conducted or are in progress to investigate the efficacy of IFNs in the treatment of SARS-CoV-2 infection (3). Type I IFNs play an important role in the early immune response to viral infections and have been shown to be effective in controlling infections such as that mediated by hepatitis C virus (HCV) (4). In addition to type I IFNs, type III IFNs also shown significant antiviral activity. Type I and type III IFNs induce the transcription of a similar set of IFN-stimulated genes with antiviral activities, albeit through different receptors (5). The expression of Type III IFNs is mainly restricted to epithelial cells in contrast to the wide distribution of type I receptors. Among them, Interferon Lambda 4 (IFNL4) has shown antiviral activity against viral infections of the upper respiratory tract, HCV, but also coronaviruses (5,6). Its importance was demonstrated by the fact that genetic variants of IFNL4 can condition the spontaneous clearance of RNA viruses. In HCV and respiratory infections, IFNL4 polymorphisms, including rs12979860, were associated to response to IFN-based therapies and spontaneous viral clearance (5,6).). In this study, we investigated whether the rs12979860 single nucleotide polymorphism (SNP) within the IFNL4 was also associated with COVID-19.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.01.21252696; this version posted March 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Patients and Methods

COVID-19 patients included in the study were attended in the Hospital San Pedro de Alcantara de Caceres, Spain. 177 patients were attended for COVID-19 among whom 45 had progressed to severe disease. A diagnosis of COVID-19 was established based on a suggestive clinical history and the detection of SARS-CoV-2 RNA in respiratory secretions. Severe COVID-19 disease was defined as dyspnea, a respiratory rate of 30 or more breaths per minute, a blood oxygen saturation of 93% or less, a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (Pao2:Fio2) of less than 300 mm Hg, or infiltrates in more than 50% of the lung field, requiring support with at least high-flow nasal cannula oxygen therapy, noninvasive ventilation, or mechanical ventilation. Samples to genotyping analysis were obtained after discharging from hospital; therefore, no death patients were included in the study. Non-COVID-19 control samples were obtained from volunteer donors before 2019 to avoid interference from possible undetected infected donors. Patients and controls gave their written informed consent and, when applicable, provided consent for banking and future analysis of biologic samples. The study was approved by the Hospital Ethical Committee for Clinical Research.

Genotyping analysis. Genomic DNA was isolated from whole blood using a Nucleospin blood kit (Macherey-Nagel, Duren, Germany). Genotyping to determining rs12979860 alleles was performed in a Stratagene 3005 MxP Quantitative PCR (Agilent Technologies, Inc., Santa Clara, CA) by using a Taqman genotyping mastermix (Thermofisher Scientific, Waltham, MA) and a commercial assay also from Thermofisher Scientific (Assay ID: C___7820464_10).

Statistical analysis. Frequency of the rs12979680 SNP among patients and controls were shows as were summarized as counts and percentages. Categorical variables were

medRxiv preprint doi: https://doi.org/10.1101/2021.03.01.21252696; this version posted March 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

compared using the chi-square test (two-sided) and Fisher's Exact Test (two-sided). A p value < 0.05 was considered to be statistically significant. Comparison analysis was to be performed by SPSS for Windows Release 17.0 (SPSS, Inc).

Results

To analyze the role of rs12979680 in SARS-CoV-2 infection, we genotyped 177 patients diagnosed with COVID-19 among whom 45 had progressed to severe disease. Table 1 summarizes the population analyzed. In this study, we only considered sex and age as risk factors associated with SARS-CoV-2 infection.

Characteristics:	**NON-COVID-19** (445)	**Total COVID-19** (177)	**Non-Severe COVID-19** (132)	**Severe COVID-19** (45)
Gender:				
Male	217 (49%)	83 (47%)	62 (47%)	21 (47%)
Female	228 (51%)	94 (53%)	72 (53%)	24 (53%)
Age (years):				
< 65	253 (57%)	74 (42%)	62 (47%)	12 (73%)
≥ 65	192 (43%)	103 (58%)	70 (53%)	33 (73%)

Table 1. characteristics of patients and controls.

The distribution of the rs12979680 SNP between patients and controls is shown in table 2. The CC genotype was significantly reduced in COVID-19 patients compared to controls (38% vs 55%, p<0.001), suggesting a protective effect of this allele. The expression of CC was also decreased when analyzed by sex, although it seemed to be more significant in females (33% vs 54%, p<0.001) than in males (43% vs 57%, p=0.039). The lower expression of CC in patients was also not affected by age (<65 years: 40% vs 56%, p=0.016; ≥65 years: 36% vs 55%, p=0.004). Finally, the percentage

medRxiv preprint doi: https://doi.org/10.1101/2021.03.01.21252696; this version posted March 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

of COVID-19 patients expressing CC was not different between non-severe and severe disease (36% vs 42%, p=0.48).

	NON-COVID-19 n=445	COVID-19 n=177	p value
rs12979860			
CC	247 (55%)	67 (38%)	<0.001
CT	161 (36%)	92(52%)	<0.01
TT	37 (8.3%)	18 (10%)	0.82
Rs12979680 CC:			
Gender:			
Male	124 (57%)	36 (43%)	<0.05
Female	123 (54%)	31 (33%)	<0.001
Age:			
< 65 years	143 (56%)	29 (40%)	<0.05
≥ 65 years	106 (55%)	38 (36%)	<0.01
Disease Severity:			
Non-Severe COVID-19		48 (36%)*	
Severe COVID-19		19 (42%)*	0.48*

Table 2. Comparation of rs12979680 between COVID-19 patients and non-COVID-19 controls.

Discussion

In this study, we have found that the rs12979680 SNP within the IFNL4 is associated with COVID-19. Our finding suggests that the expression of the CC allele appears to confer protection against this disease. This observation correlated with the protection conferred by this allele during HCV and respiratory viral infections (4-6).

medRxiv preprint doi: https://doi.org/10.1101/2021.03.01.21252696; this version posted March 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

IFNL4 has been found to exert antiviral activity against HCV, but also against several coronaviruses (5). However, the production of IFNL4 appears to be a disadvantage during HCV infection. Thus, the TT allele of the rs368234815 polymorphism disrupts the expression of IFNL4 (7). This inactivation of the IFNL4 gene has been correlated with the spontaneous clearance to HCV and with response to type I IFNs-based treatments. The rs12979680 polymorphism that we have analyzed is in strong linkage disequilibrium with rs368234815, and both polymorphisms have shown similar performance as predictors of viral clearance and response to IFNs treatments (8). Our findings suggest that like HCV and other viral infections, IFNL4 may play an important role in COVID-19. This observation may help to understand the disproportionate prevalence of COVID-19 in the black population with a lower frequency of the protective CC allele than in the white population (6, 9). The fact that there were no significant differences in CC expression between non-severe and severe disease proposes a role for IFNL4 in early stages, but not in disease progression as previously suggested (10).

As antiviral agents, IFNs are being investigated as treatments for COVID-19. However, their efficacy is somehow contradictory (3). One explanation proposed that the timing of IFN administration is important as early IFN treatments appeared to decrease, but late treatments increase mortality. Our findings added a new complementary explanation. In HCV infection, rs12979680 was shown to be associated with response to IFNs-based treatments. It may also be possible that this polymorphism also affects responses to IFN-based treatments in COVID-19 patients. The fact that the frequency of CC varies among races and is lower in COVID-19 patients may mask the effectiveness of these treatments.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.01.21252696; this version posted March 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

We believe that the data shown in this study is of great interest as we show that IFNL4 polymorphisms may be potential markers of COVID-19 disease. However, further studies are needed to strengthen the observations presented. The analysis of polymorphisms in asymptomatic people and their association with comorbidities would help to decipher the role of IFNL4 in the COVID-19 disease.

In summary, we have found that an IFNL4 polymorphism is associated with COVID-19, opening a new way of understanding the mechanisms of the disease, but also in the design of treatments, the understanding of racial differences and the planning of vaccination campaigns given the shortage of vaccines.

References

1. Vabret N, GJ Britton, C Gruber, S Hegde, J Kim, , et al. Immunology of COVID-19: Current State of the Science. Immunity. 2020; 52:910-941.6.

2. Kalil AC, TF Patterson, AK Mehta, KM Tomashek, CR.Wolfe, , et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2020, Dec 11. doi: 10.1056/NEJMoa2031994.

3. Wang **N**, Y Zhan, L Zhu, Z Hou, F Liu, et al. Retrospective Multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe. 2020;28:455-464.e2.

4. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401. doi:10.1038/nature08309

medRxiv preprint doi: https://doi.org/10.1101/2021.03.01.21252696; this version posted March 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

5. Hamming OJ, E Terczyńska-Dyla, G Vieyres, R Dijkman, SE Jørgensen, et al. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 2013;32:3055-65. doi: 10.1038/emboj.2013.232

6. Rugwizangoga B, ME Andersson, JC Kabayiza, MS Nilsson, B Ármannsdóttir, et al. IFNL4 Genotypes Predict Clearance of RNA Viruses in Rwandan Children With Upper Respiratory Tract Infections. Front Cell Infect Microbiol. 2019;9:340. doi: 10.3389/fcimb.2019.00340.

7. Prokunina-Olsson L, B Muchmore, W Tang, RM Pfeiffer, H Park, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013;45: 164–171.

8. Real LM, K Neukam, R Herrero, JM Guardiola, T Reiberger, et al. IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. PLoS One. 2014;9:e95515. doi: 10.1371/journal.pone.0095515.

9. Eboni G. Price-Haywood, Jeffrey Burton, Daniel Fort, and Leonardo Seoane. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med 2020;382:2534-2543. doi: 10.1056/NEJMsa2011686.

10. Amodio E., RM Pipitone, S Grimaudo, P Immordino, CM Maida, et al. SARS-CoV-2 viral load, ifnλ polymorphisms and the course of COVID-19: an observational study. J Clin Med 2020;9: 3315. doi:10.3390/jcm9103315.